Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New PD-1 Immunotherapy Combinations Push The Envelope In Melanoma

Executive Summary

Early data from small studies presented at the Society of Melanoma Research meeting suggest potential for safely and effectively combining PD-1 inhibitors with a range of drugs, including Amgen’s Imlygic vaccine.

Advertisement

Related Content

New Melanoma Frontier Opens To Bristol's Opdivo And Novartis/Glaxo's BRAF/MEK Combo
OncoSec Pushes IL-12 Approach Forward In PD-1 Melanoma Failures
Melanoma Approvals Break New Ground In Immunotherapy
Amgen’s Imlygic Approval A Milestone For Oncolytic Cancer Vaccines
Opdivo/Yervoy Data Show Role For Checkpoint Combos; ASCO Debates Biomarkers

Topics

Related Companies

Related Deals

What to read next

Advertisement
UsernamePublicRestriction

Register

PS057293

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel